Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LY3962681 in Healthy Volunteers and Parkinson's Disease (PROSPECT-PD)
NCT06565195Phase 1Recruiting
- Sponsor
- Prevail Therapeutics Inc.
- Start
- Aug 2024
- Primary completion
- Jul 2030
- Modality
- Gene Editing, Gene Silencing, Conjugated siRNA
- Countries
- 5
01
Overview
Phase 1, randomised, double-blind trial of LY3962681 in Parkinson's disease (PD) (4 arms), sponsored by Prevail Therapeutics Inc. Primary endpoints: Incidence of Serious Adverse Events at 76 weeks, Incidence of Treatment Emergent Adverse Events at 76 weeks and 1 more. Started Aug 2024; status: recruiting.
02
Drugs
LY3962681
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT06565195.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06565195.